The frequency of systemic recurrences observed in women suffering from ER-positive/HER2-negative diseases could be ascribed to the fact that only 14% of these women received chemotherapy, whereas 40% of the women with triple-negative tumours and 65% of the women with HER2-positive tumours received chemotherapy. Here, ERBB2 is linked to neoplasm.